Pipeline Catalysts Key Focus For Roche’s H1 Update
Swiss Pharma’s Increasing Diversification Also Big Theme
Despite legacy cancer drug sales still being hurt by biosimilars, Roche at the half-year mark is expected to give another good overall performance and underscore its growing product diversity and an increasing interest in rare diseases.
